Enveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives
New patent provides additional composition of matter and methods of use claims for Enveric’s tryptamine-derived prodrugs including EB-373, a new chemical entity psilocin prodrug CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences (NASDAQ: ENVB)…
Details